Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
Oric-114 Dose 1 + Amivantamab, Oric-114 Dose 2 + Amivantamab, Oric-114 Dose 3 + Amivantamab
Solid Tumors, Nsclc, Egfr Exon 20 Insertion Mutations, Egfr-Mutated Nsclc
Phase I
Recruiting
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
Feb 03, 2025
―
Oric-944, Abiraterone Acetate (Zytiga®) 250 Mg Or 500 Mg Tablets, Apalutamide (Erleada™) 60 Mg Or 240 Mg Tablets, Darolutamide (Nubeqa®) 300 Mg Tablets, Enzalutamide (Xtandi®) 40 Mg Capsules Or 40 Mg And 80 Mg Tablets
Metastatic Prostate Cancer
Phase I
Recruiting
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Jun 07, 2022
―
Chemotherapy Drug, Oric-114
Solid Tumors
Phase I/II
Recruiting
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Mar 24, 2022
―
Oric-533
Relapsed Or Refractory Multiple Myeloma
Phase I
Completed
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Feb 02, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Oric Pharmaceuticals (ORIC) have in its pipeline
ORIC is currently developing the following drugs: Oric-114 Dose 1 + Amivantamab, Oric-114 Dose 2 + Amivantamab, Oric-114 Dose 3 + Amivantamab, Oric-944, Abiraterone Acetate (Zytiga®) 250 Mg Or 500 Mg Tablets, Apalutamide (Erleada™) 60 Mg Or 240 Mg Tablets, Darolutamide (Nubeqa®) 300 Mg Tablets, Enzalutamide (Xtandi®) 40 Mg Capsules Or 40 Mg And 80 Mg Tablets, Chemotherapy Drug, Oric-114. These drug candidates are in various stages of clinical development as the company works toward FDA approval.